Therefore, these data could indicate that if we had a targeted therapy that increased the expression of SLFN12, then the SLFN12_Upreg signature genes would be further upregulated and the SLFN12_Dnreg signature genes would be further downregulated in the African American population, which could lead to a better breast cancer survival rate. This evidence concerns the gene SLFN12 and breast cancer.